Bio Usawa and ServareGMP Partner to Establish Monoclonal Antibody Manufacturing in Africa
核心洞察
Bio Usawa Biotechnology (搜索) and ServareGMP (搜索) announced a strategic partnership to build advanced monoclonal antibody (搜索) manufacturing capabilities in Africa, addressing critical healthcare access gaps in low- and middle-income countries.
The collaboration focuses on four core pillars: local biomanufacturing infrastructure, workforce development, process innovation for cost reduction, and emergency response capabilities for pandemics and health crises.
The partnership aims to fundamentally restructure how biotherapeutics are developed, produced, and delivered in LMICs by investing in local talent, infrastructure, and innovation to ensure equitable access to life-saving therapies.
Bio Usawa Biotechnology (搜索) Ltd. and ServareGMP (搜索) announced a strategic partnership to establish advanced monoclonal antibody (搜索) manufacturing capabilities in Africa, directly addressing the critical healthcare access gap affecting patients in low- and middle-income countries (LMICs). The collaboration was announced on July 23, 2025, from Kigali, Rwanda, San Francisco, and San Diego.
Four-Pillar Strategic Framework
The transformative collaboration spans four core pillars designed to revolutionize biotherapeutic access across Africa:
Local Biomanufacturing Infrastructure: Building and operating advanced GMP manufacturing facilities in Africa for the production of high-quality monoclonal antibodies.
Workforce Development & Training: Implementing industry-leading training programs to cultivate a skilled biopharma workforce across the continent.
Process Innovation: Deploying next-generation process optimization and cost-reduction technologies to make antibody therapies more affordable.
Emergency Response Capability: Establishing rapid development and deployment protocols for mAbs to respond to pandemics and regional health crises.
Leveraging Combined Expertise
The partnership combines Bio Usawa's deep understanding of African healthcare markets with Servare's extensive biopharmaceutical development expertise. Together, the organizations bring decades of proven experience across biotherapeutic development, clinical testing, current Good Manufacturing Practice (cGMP), regulatory approvals, and global commercialization of breakthrough biomedicines, including many of the leading blockbuster therapies on the market today.
"ServareGMP (搜索) was founded on the belief that world-class biomanufacturing should be globally distributed," said Gary Pierce, Executive Director of ServareGMP. "Through this collaboration, we are not only addressing immediate healthcare needs but also building sustainable infrastructure that will benefit future generations of African patients. Together, we will impact African healthcare by empowering communities and saving lives."
Building Healthcare Self-Reliance
"This initiative is about more than medicine—it's about building self-reliance, equity, and resilience," said Richard Chin, M.D., Bio Usawa's co-founder and Chair of the Board of Directors. "We are proud to co-create a future in which life-saving therapies are widely available at an affordable price for patients in Africa and in other LMICs. We are building the foundation for a more just and resilient global healthcare system."
Addressing Critical Access Barriers
Monoclonal antibodies are a cornerstone of modern medicine. However, cost and access barriers prevent their widespread use in many LMICs. This partnership will change that by enabling local production and distribution—cutting costs, reducing reliance on imports, and improving response times in health emergencies.
The partnership extends beyond cost reduction to fundamentally restructure how biotherapeutics are developed, produced, and delivered in LMICs. By investing in local talent, infrastructure, and innovation, the partnership seeks to ensure that patients in Africa can access the same life-saving therapies as those in high-income countries—both during crises and for ongoing care.
Strategic Context and Previous Initiatives
This collaboration is grounded in a shared commitment to addressing the growing therapeutic access disparity in LMICs. The partnership's strategic focus aligns with recent initiatives by both organizations: Servare's collaboration with the Coalition for Epidemic Preparedness Innovations (搜索) (CEPI) to develop countermeasures against the Nipah virus (搜索), and Bio Usawa's partnership with Bioeq AG (搜索) for BioUcenta (搜索), a biosimilar of Lucentis® targeting retinopathies (搜索) in Sub-Saharan Africa.
Bio Usawa is a leading African biotechnology company dedicated to expanding access to affordable, high-quality biosimilars across the continent. Through strategic industry partnerships and deep regional expertise, Bio Usawa is pioneering a future where life-saving biomedicines are developed, manufactured, and distributed by Africans, for Africans—and beyond.
ServareGMP (搜索) is a specialized non-profit biotechnology organization founded by industry veterans with extensive experience across the biopharmaceutical value chain. The organization's leadership team brings proven expertise spanning discovery, development, manufacturing, regulatory approval, and commercialization of innovative therapeutics.